🔴 Ironwood Pharmaceuticals is trading 5.4% down today with no clear company-specific catalyst

Ironwood Pharmaceuticals is trading 5.4% down at $4.08, with no clear company-specific catalyst identified in August 13, 2026 coverage.

• Recent second-quarter results raised full-year 2026 guidance, including LINZESS sales of $1.15 billion–$1.20 billion and revenue of $460 million–$485 million.
• That positive update does not explain today’s decline; broader markets are higher, so the move is not clearly aligned with overall risk sentiment.
• The reason remains unclear and may reflect profit-taking or trading-specific pressure.